Select Location & Language

grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Press Release

January 30, 2020

Omnicell to Release Fourth Quarter 2019 Earnings Results on February 6, 2020

Download PDF

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jan. 30, 2020-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, February 6, 2020, to discuss the Company’s Fourth Quarter 2019 financial results.

What:

 

Omnicell Fourth Quarter 2019 earnings conference call and webcast

   

When:

 

February 6, 2020, 1:30 p.m. PT

   

Who:

 

Randall Lipps, chairman, president, chief executive officer, and founder

 

 

Peter Kuipers, chief financial officer

   

Where:

 

The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 5679705.

 

 

The webcast can be accessed at:

 

 

http://ir.omnicell.com/communications/events-presentations

 

 

 

Replay:

 

Available starting at 4:30 p.m. PT on February 6, 2020, through 11:59 p.m. PT on March 19, 2020. Dial 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # 5679705

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and expert services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 40,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

OMCL-E

Source: Omnicell, Inc.

Peter Kuipers
Omnicell, Inc.
(650) 251-6100
peter.kuipers@omnicell.com